1. Home
  2. CATO vs MGNX Comparison

CATO vs MGNX Comparison

Compare CATO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CATO
  • MGNX
  • Stock Information
  • Founded
  • CATO 1946
  • MGNX 2000
  • Country
  • CATO United States
  • MGNX United States
  • Employees
  • CATO N/A
  • MGNX N/A
  • Industry
  • CATO Clothing/Shoe/Accessory Stores
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CATO Consumer Discretionary
  • MGNX Health Care
  • Exchange
  • CATO Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • CATO 88.2M
  • MGNX 99.7M
  • IPO Year
  • CATO N/A
  • MGNX 2013
  • Fundamental
  • Price
  • CATO $4.32
  • MGNX $1.81
  • Analyst Decision
  • CATO
  • MGNX Hold
  • Analyst Count
  • CATO 0
  • MGNX 6
  • Target Price
  • CATO N/A
  • MGNX $3.20
  • AVG Volume (30 Days)
  • CATO 48.0K
  • MGNX 630.9K
  • Earning Date
  • CATO 11-20-2025
  • MGNX 11-04-2025
  • Dividend Yield
  • CATO N/A
  • MGNX N/A
  • EPS Growth
  • CATO N/A
  • MGNX N/A
  • EPS
  • CATO N/A
  • MGNX N/A
  • Revenue
  • CATO $650,830,000.00
  • MGNX $165,495,000.00
  • Revenue This Year
  • CATO N/A
  • MGNX N/A
  • Revenue Next Year
  • CATO N/A
  • MGNX N/A
  • P/E Ratio
  • CATO N/A
  • MGNX N/A
  • Revenue Growth
  • CATO N/A
  • MGNX 303.47
  • 52 Week Low
  • CATO $2.19
  • MGNX $0.99
  • 52 Week High
  • CATO $6.70
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • CATO 52.43
  • MGNX 51.87
  • Support Level
  • CATO $4.16
  • MGNX $1.69
  • Resistance Level
  • CATO $4.67
  • MGNX $1.83
  • Average True Range (ATR)
  • CATO 0.16
  • MGNX 0.10
  • MACD
  • CATO -0.05
  • MGNX 0.00
  • Stochastic Oscillator
  • CATO 23.90
  • MGNX 56.00

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: